Teun van Gelder is a Professor in Clinical Pharmacology, as well as an internist-nephrologist and clinical pharmacologist in the Department of Hospital Pharmacy and Department of Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands.

Professor van Gelder was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a postdoctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr Randall E Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during that time.

Professor van Gelder’s current research at the Erasmus Medical Center is focused on clinical pharmacology and therapeutic drug monitoring. He is the chairman of the Dutch Society for Clinical Pharmacology and president-elect of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology. 

Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory Med/Pathology, Mayo Clinic College of Medicine.

Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.

Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation of Clinical Chemistry And Laboratory Medicine (IFCC) and IATDMCT.

She has over 47 peer reviewed publications, 12 book chapters, over 60 abstracts and over 100 presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.

Dr. Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.  He teaches clinical pharmacology to medical students and post-graduate students. He is an Adjunct Faculty of University of Florida, College of Pharmacy.

He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983.  He started working in the field of TDM since 1985 when he joined with Kyoto University Hospital as a faculty member responsible for TDM.  His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine.  Oncology and infectious diseases are his major fields for research.  He applied population pharmacokinetic and pharmacodynamic modeling to a number of new drug development as well as rational use of drugs for patient care such as clinical implementation of TDM.  Recently, he also investigates multi-omics biomarkers including pharmacogenomics, proteomics and metabolomics as a novel indicator to predict responder/non-responder variation to drug therapy.  He published more than 180 peer-reviewed original articles and 282 book chapters and review articles. He was distinguished as one of the “ISI Highly Cited Researchers” by Thomson Reuters ISI database.

He served as Secretary of the IATDMCT for 4 years, and Chair of the 15th Congress of IATDMCT in Kyoto, 2017.  He was a past President of Japanese Society of Therapeutic Drug Monitoring (JSTDM).

Dr. med. Maria Shipkova received her medical education at the Medical University, Sofia, Bulgaria, where she specialized in Laboratory Medicine. In 1992 she joined the TDM laboratory headed by Prof. Dobrin Svinarov, Chair for Clinical Laboratory, Sofia. In 1995 Dr. Shipkova was awarded a Tempus Phare postdoctoral fellowship from the European Union to broaden her education in therapeutic drug monitoring at the Department of Clinical Chemistry, Georg-August-University, Göttingen, under its Director, Prof Michael Oellerich. At the conclusion of this appointment she remained in Göttingen as a resident and was involved in a variety of routine and research activities in the field of transplantation and immunosuppressive drug monitoring. In 2003 Dr. Shipkova moved to Stuttgart, where she now pursues her work in the field of the therapeutic drug monitoring as a Senior Scientist at the institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart. She is responsible for the therapeutic drug monitoring/toxjcology section.

In 2005 Maria Shipkova was awarded with the Young Investigator Award of the International Society for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Her research interests are focused on drug metabolism & drug toxicity, development & evaluation of analytical methods, and most recently biomarkers as a tool to optimize immunosuppressive therapy.

Dr. Shipkova has authored over 100 peer- reviewed publications and has supervised several doctoral theses and post-doc fellows in the field of the therapeutic drug monitoring. She was the Chair of the IATDMCT immunosuppressive Drugs Scientific Committee (2013-2015) and IATDMCT Director of Education (2015 – 2017). Dr Shipkova is currently Vice-Chair of the Communications Committee of the IATDMCT. She has held the following positions: Coordinator "TDM of Everolimus" Consensus Project (2013-2016), Member of the IATDMCT Biomarkers in transplantation Working Group (2009 -), Associated member of the Bulgarian Academy of Science and Arts, past Editor in Chief of the IATDMCT Newsletter "Compass" (2009 - 2015).

Since September 2012, Denise has worked as a Forensic Toxicologist at Forensic Medicine and Science (FMS), University of Glasgow. Prior to this she worked for just under 10 years at Analytical Services International, St George’s - University of London under the supervision of IATDMCT Past-President Professor David W Holt. In both positions she has pursued her interest in bioanalytics; she specialises in the development and validation of hyphenated chromatographic and mass-spectrometric methods for the qualitative and quantitative detection of drugs, their metabolites and endogenous compounds for application in the areas of forensic and clinical toxicology. In her current position Denise is also a reporting Forensic Toxicologist and Expert Witness responsible for interpretation and communication of toxicological finding to the Scottish Courts.

For 12 years, Denise has been an active member of IATDMCT with a successful committee history. During a decade on the Young Scientists Committee as Vice-Chair then Chair, YS membership increased from 8 to 296 members. Denise was also the founding chair of the very active Communications Committee, who are integral to association activities. Denise looks forward to devoting the same enthusiasm to her role as IATDMCT Treasurer.

Employment:

• Sep 2012-Present: Forensic Medicine and Science (FMS), University of Glasgow, UK
• Forensic Toxicologist

• Dec 2002-Sep 2012: Analytical Services International (ASI), St George’s, University of London, UK
  Senior Scientist in Clinical and Forensic Toxicology

Education & Certification:

• Sep 1996-June 2002: University of Strathclyde, Glasgow, UK
  MSci in Forensic and Analytical Chemistry

Professional Activities:

• Member of International Association of TDM & Clinical Toxicology (IATDMCT)
  Sep 2017-Present: Treasurer of IATDMCT
  Jan 2012-Dec 2017: Communications Committee (CC) Chair
  (activities coordinated by CC: E-News, Social Media, Blog, Website / Resources Area, Compass etc)
  Oct 2011-Oct 2015: Young Scientist Committee (YSC) Chair
  (coordinated all YS activities: Congress YS workshops/symposia, social events and awards, and all non-Congress educational activities)
  Sep 2007-Oct 2015: Compass Associate Editor
  Apr 2005-Oct 2011: Young Scientist Committee (YSC) Vice-Chair
• Member of The International Association of Forensic Toxicologists (TIAFT)
• Member of UK and Ireland Association of Forensic Toxicologists (UKIAFT)
• Member of London Toxicology Group (LTG)
• Member of Royal Society of Chemistry (MRSC)
• Invited speaker and presented at national and international meetings
• Contributed to to several peer-reviewed publications and book chapters
• Visiting Lecturer, Queen Mary, University of London (Oct-2010-Present)

Katharina M. Rentsch studied pharmacy at the ETH in Zurich, Switzerland and obtained the pharmacist's license in 1988. Thereafter she got a certification as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology in 1991. In 1996 she finished her PhD thesis on TDM of cytostatic drugs at the ETH Zurich. In 2003 she finished her habilitation in the field of clinical chemistry at the department of chemistry and applied biosciences of the ETH Zurich and in 2007 she habilitated at the medical faculty of the University Zurich, Switzerland. In 2010 she became an adjunct professor at the medical faculty of the University Zurich and in 2012 at the medical faculty of the University Basel. In 2007 she certified as a clinical toxicologist GTFCh.

From 1994 to 2011 Dr Rentsch has been the head of the laboratory for drug analysis and clinical toxicology at the Institute for Clinical Chemistry, University Hospital Zurich. Since December 2011 she is the head of the division of clinical chemistry at the University Hospital Basel, Switzerland. Since May 2014 head of the laboratory medicine at the University Hospital Basel, Switzerland.

Her main research interest is the development of new analytical methodologies for TDM and CT, and their application in different clinical studies as well as the implementation of TDM procedures for new drugs. She is author or co-author of over 150 peer-reviewed publications, 8 book chapters and over 60 published oral or poster presentations.

Dr Rentsch is a member of and serves on committees for several professional organizations including: Swiss Society of Clinical Chemistry (SSCC), the International Association of Forensic Toxicology (TIAFT), the American Association for Clinical Chemistry (AACC), the German Society of Toxicological and Forensic Chemistry (GTFCh) and IATDMCT. Since 2006 she is member of the IATDMCT Clinical Toxicology/Drugs of Abuse Committee and has been a member of the scientific board of the Basel Meeting in 2003 and of the local organizing meeting of the Stuttgart Meeting in 2011.

Dr. Erik van Maarseveen got his Pharmacy Degree in 2005 and started his career as a pharmacist at the Gouda Hospital (The Netherlands). That same year he obtained the Certificate of Fundamentals of Business & Economics for Beta’s as part of the Master program “Business and Economics for Beta’s” at Utrecht University.  His 4-year-training as a hospital pharmacist commenced in 2006 at Central Hospital Pharmacy, The Hague and the Gouda Hospital. Dr. van Maarseveen has been working as a registered hospital pharmacist since 2010 at the University Medical Center Utrecht (The Netherlands), where he leads the therapeutic drug monitoring and toxicology laboratory which is equipped with GC, HPLC, UPLC, LC-MSMS and Orbitrap-LCMS techniques.

Dr. van Maarseveen and his team develop bio-analytical assays primarily for therapeutic drug monitoring and clinical toxicology purposes with the ultimate goal to improve treatment outcomes. Directly after he obtained his PhD on optimizing treatment of once daily dosed aminoglycosides and continuously infused vancomycin, he embarked on his clinical pharmacologist training, which he completed in 2016. Currently, his research focusses on clinical pharmacology and clinical mass spectrometry in solid organ and stem cell transplantation, infectious diseases, cystic fibrosis and oncology. Among others, he is co-applicant of a grant of the Dutch KiKa (Children Cancerfree) foundation awarded to investigate the pharmacology of conditioning agents in stem cell transplantation conditioning. Van Maarseveen is a member of the TDM in Oncology scientific committee of the IATDMCT association, chair of the special interest group on Transplantation and member of the committee on Analysis & Toxicology of the Dutch Association for Hospital Pharmacists. In 2016, he was installed as a board member of the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology.

Furthermore, Dr van Maarseveen, who is in possession of a University Teaching Qualification,  teaches pharmacology, TDM and toxicology to both pharmacy and medical students at Utrecht University. Dr van Maarseveen has published over 35 peer-reviewed papers (https://www.researchgate.net/profile/Erik_Van_Maarseveen2) and acts as a reviewer for several clinical and pharmacology journals. In 2015 he was granted the award for best publication by the Dutch Association for Hospital Pharmacists.

Staffan Rosenborg graduated as an MD from Karolinska Institutet in 1996. He became a specialist in Nephrology in 2003 and in Clinical Pharmacology in 2007. Dr Rosenborg defended his PhD thesis “CYP2C dependent drug metabolism in vivo – influence of genetics and drug interactions” in 2010. Prof Teun van Gelder was the external examiner.
Dr Rosenborg was Head of Residents and Director of post-graduate training in Clinical Pharmacology at the Karolinska University Hospital between 2010 and 2013. From 2013 he has been the Head of the Clinical Pharmacology Trial Unit (CPTU) at the same hospital. The CPTU is a phase-I trial unit certified for first-in-human trials. Dr Rosenborg was awarded the Swedish Diploma in Clinical Trials in June 2016.

He is the secretary of the Swedish Foundation for Clinical Pharmacology and Pharmacotherapy and is also one of two Swedish representatives in the Section for Pharmacology of the Union Européenne des Médecines Spécialistes (UEMS). He has more than 500 lecturing hours, has organized courses in clinical pharmacokinetics and has participated in courses on leadership in postgraduate education.

Dr Rosenborg has some 20 peer reviewed publications in international journals and some 15 papers in Swedish journals. His areas of expertise include: different aspects of nephropharmacology (including drug dosing in dialysis), immunosuppressive drugs, pharmacokinetics,  therapeutic drug monitoring, clinical trial design and conduct.

Current Appointments

• Senior Specialist in Clinical Microbiology and Infectious Diseases St. Vincent's Hospital, Sydney (1985 - to date)
• Clinical Director, Antimicrobial Therapeutic Drug Monitoring Group, St. Vincent’s Hospital, Sydney (2012 – to date)
• Visiting Medical Officer St. Vincent's Private Hospital, Sydney (1985 – to date)
• Visiting Medical Officer Sacred Heart Hospice, Sydney (1985 – to date)
• Conjoint Associate Professor, School of Medicine, University of New South Wales (2000 – to date)
• Adjunct Professor, Faculty of Science University of Technology, Sydney (2002 -to date)
• Associate Editor, Transplantation (2014 – to date)

Certifications

• Fellow of the Royal College of Pathologists of Australasia (FRCPA) 1986
• Fellow of the Royal Australasian College of Physicians (FRACP) 1985
• Bachelor of Medicine and Bachelor of Surgery, Honours Class I 1977
• Bachelor of Science (Medicine) Honours Class I 1974

Current Memberships - Professional Societies

• Royal Australasian College of Physicians
• Royal College of Pathologists of Australasia
• Australasian Society for Infectious Diseases
• Australasian Society for HIV Medicine
• American Society for Microbiology
• Australasian Society for Antimicrobials
• Infectious Diseases Society of America
• International Society for Heart and Lung transplantation
• International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• Transplant Infectious Diseases
• European Society for Clinical Microbiology and Infectious Diseases
• The Transplant Society
• Animal Management in Remote and Indigenous Communities

Selection of Professional Activities (all to date unless otherwise indicated)

• 1986- Member, Drug and Therapeutics Committee, St. Vincent's Hospital
• 1988 - Accreditor, National Association of Testing Authorities
• 1989-97 Member, N.S.W. State Committee, Royal Australasian College of Physicians
• 1990- Examiner, Royal Australasian College of Pathologists
• 1993 – 2014 Member, Tuberculosis Advisory Committee, N.S.W. Department of Health
• 1995 Visiting lecturer, University Santo Tomas, Manila, Philippines
• 1997-99 President, Australasian Society for HIV Medicine
• 2000-10 Member, Pharmacology and Toxicology Working Group, National Centre in HIV Epidemiology and Clinical Research
• 2009-13 Co-chair, Australian and New Zealand Mycoses Interest Group
• 2010 - Examiner, Royal Australasian College of Physicians
• 2012- Scientific Committee member (HIV and Infectious Diseases), International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• 2012- Scientific Committee member, International Society for Heart and Lung Transplantation • 2012- Scientific Committee member, Transplant Infectious Diseases
• 2013- President, Transplant Infectious Diseases
• 2013- Board Member, Medical Advances without Animals
• 2014 - Visiting Lecturer, The Academy of Medicine, Singapore
• 2014- Visiting International Professor, Royal College of Pathologists of Australasia

• Approximately 160 publications in refereed journals
• Joint lead, IATDMCT Guidelines on TDM of Echinocandins
• Author, Therapeutic Drug Monitoring of Antifungal Agents Used in Patients Post Cardiothoracic Transplantation or with a Mechanical Circulatory Device. The 2014 International Society for Heart and Lunch Transplantation Guidelines for Management of Fungal Infections in Mechanical Circulatory Support and Cardiothoracic Organ Transplant Recipients. (In press).
• Proposer and Co-Convener – joint IATDMCT/TID/The Transplant Society (TTS) Conference, Hong Kong, 2016 in conjunction with TTS Conference
• Keynote and invited speaker at many national and international meetings including ICAAC (Denver 2012), IATDMCT (Salt Lake City 2012), ISHLT (Montreal, 2012; San Diego, 2013), The World Transplant Congress (San Francisco 2014), Transplant Infectious Diseases (Berlin, 2012; Vienna, 2013; Barcelona 2014), ISHAM (Melbourne 2015)
• Convener and speaker at a number of regional Mycology Master Classes run under the auspices of the International Society of Human and Animal Mycology (ISHAM) including Phuket (2011), Singapore (2012), Seoul (2013) and Penang (2014).
• Extensive connections with the Asian region and an invited speaker at many conferences within Asia, including Malaysia, Hong Kong, Singapore, Indonesia, Japan and China.
• Coordinator of the Clinical Stream at the forth-coming ISHAM conference in Melbourne (May 2015) and convener of the pre-congress workshop on Therapeutic Drug Monitoring in Fungal Infections.
• Reviewer of approximately 15 manuscripts per year for the past 5 years in local and international journals

Prof. Dr. Markus R. Meyer is a full Professor of Pharmacology & Toxicology at the Faculty of Medicine and at the Faculty of Pharmacy, Saarland University and head of the Department of Experimental and Clinical Toxicology at the Saarland University in Homburg, Germany. After he was promoted to PhD and gained his habilitation (venia legendi in pharmacology and toxicology) from the Saarland University, he moved to the Department of Clinical Pharmacology at the Karolinska Institutet in Stockholm, Sweden and thereafter to the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital, Germany. His main area of research is analytical toxicology including in-vitro and in-vivo toxicokinetics.

He has published over 120 peer-reviewed original papers or review articles and received several international and national scientific awards amongst them the TIAFT Achievement Award and the GTFCh Young Scientist Award. Besides IATDMCT, Prof. Meyer is member of several international and national scientific societies such as the TIAFT, GTFCh, DGPT, and DGMS.  He is currently IATDMCT board member and chair of the YS committee of the IATDMCT as well as vice chair of the TIAFT YS committee.

Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, biomarker control, simulation, and most importantly, use of models to optimize therapy for individual patients. He is a practicing pediatric infectious diseases specialist. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on anti-infective compounds, he has experience with other therapeutic areas.

Michael Neely is the Acting Chief of Infectious Diseases and Director of the Laboratory of Applied Pharmacokinetics and Bioinformatics (LAPKB) at the Children's Hospital of Los Angeles and an Associate Professor of Pediatrics and Clinical Scholar at the University of Southern California (USC) Keck School of Medicine. He created Pmetrics, a non-parametric and parametric population modeling and simulation package for R based on over four decades of work by members of LAPKB. He also created an R package for LAPKB’s BestDose software to optimize drug therapy for individual patients. He works with multidisciplinary faculty collaborators in the USC Departments of Pediatrics, Medicine, and Preventive Medicine, as well as in the School of Pharmacy.

Dr. Neely has a Master’s of Science in Clinical and Biomedical Investigations from USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling. He was a member of the United States Food and Drug Administration Anti-infective Drug Advisory Committee and now periodically consults for the committee. He is a Regent of the American College of Clinical Pharmacology, a founding member of the International Society of Pharmacometrics, and an active member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He has been the PI on an NIH K23 training grant, two R01s, and is co-PI of a third R01, as well as co-investigator on numerous other NIH grants, with continuous NIH funding since 2007.

Michael Neely has published more than 100 peer-reviewed articles, mentored numerous visiting scholars, and is an invited speaker worldwide.

Employment

• PhD student
  • 1999-2003 Ghent University (Faculty of Medicine & Health Sciences)
• Postdoctoral researcher
  • 2004-2007 Ghent University (Faculty of Sciences)
  • 2007-2013 Ghent University (Faculty of Pharmaceutical Sciences)
• Assistant-Professor (‘Docent’)
  • Since Feb 2013 Ghent University (Faculty of Pharmaceutical Sciences)

Education & Certification:

• 1999 Pharmacist
• 2004 PhD in Medical Sciences

Professional Activities:

Activities specifically related to IATDMCT

• Meetings:
  • First meeting in Stuttgart in 2011
  • Prize for best poster/poster presentation at the 2011 meeting
  • Participated to the 2013 and 2015 meetings (always with an active contribution (oral and/or poster)
  • Will participate to the 2017 meeting
• Alternative Sampling Strategies Committee:
  • Member since 2011
  • Chair from 2011-2015
  • Vice-chair since 2015
  • Actively engaged in:
    • Organising workshops, roundtables, scientific sessions, etc. for the International Congresses in Salt Lake City, Rotterdam and Kyoto
    • Providing contributions to the Compass on a regular basis
• Organizer of a successful IATDMCT Satellite Symposium in 2015
  • Alternative Sampling Strategies in Toxicology and Therapeutic Drug Monitoring
  • 176 registrants from 22 countries
  • [insert bio image here]
• Young Scientist member
  • Active member since the start of membership
  • Co-represented young scientists at the 2015 meeting of the Japanese Society of Therapeutic Drug Monitoring
• Referee for the journal Therapeutic Drug Monitoring
• Core research activities align very well with the scope of IATDMCT

Teaching activities
Responsible for the following courses at Ghent University:

• Toxicology (2nd Master)
• General Toxicology (3rd Bachelor)
• Bioanalysis (Master)
• Chemical Criminalistics (Master)
• Drug Toxicity (Master)
• Supplements in Toxicology: advanced studies (MaNaMa Clinical Biology)
• Co-responsible for Bioanalytical Practical Course

Research Activities (general):

1. Publications: Summary:
   • 77 A1 articles published or in press; 2 proceedings; 1 Book as Editor, 4 Book Chapters
   • # (%) in different quartiles: Q1: 66% – Q2: 29% – Q3: 4% – Q4: 1%
     Average positioning: 20% - Median positioning: 18%
     # in top 10%: 20 (26%) - # in top 5 of a category: 14 (18%)
   • 51 articles as 1st, 2nd or last author
   • 1186 Times Cited (ISI Web of Knowledge → Web of Science, 01/03/2017)
   • Average Impact Factor: 4.497; Median Impact Factor: 3.436
   • h-index (# articles with # of citations): 21
2. Promotor of 4 defended PhD’s and >10 ongoing PhD’s
3. 3 main research lines can be distinguished:
   • Alternative sampling strategies (e.g. dried blood microsampling, hair analysis)
   • Development of bio-assays for monitoring of activation of G-protein coupled receptors
   • Analysis of vitamers (amongst which folates), their precursors and degradation products, in plant material and biological material (blood)
4. Referee for > 30 journals (currently about 1 review/week)
5. Involved in the activities (e.g. regional editor; member of scientific committees) of main international scientific organisations (e.g. TIAFT and IATDMCT); Former chair of the Alternative Sampling Strategies Committee of IATDMCT.
6. Organizer of intra-faculty conferences, as well as an international conference on “Alternative Sampling Strategies in Toxicology and Therapeutic Drug Monitoring” (Sep 2014, 176 registrants). Main co-organizer of the TIAFT2018 meeting, to be held in August 2018 in Ghent (anticipated number of attendants: 600-700).
7. > 100 oral and poster presentations at national and international conferences
8. Member of the reading or examination committee of >30 PhD theses (national & international)
9. Member of scientific societies:
   • Toxicological Society of Belgium and Luxemburg (BLT) (Board Member);
   • BelTox (Belgian Society of Toxicology and Ecotoxicology);
   • Belgian Environmental Mutagen Society (Board Member);
   • Belgian Society of Mass Spectrometry (BSMS);
   • American Chemical Society (ACS);
   • The International Association of Forensic Toxicologists (TIAFT);
   • International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT);
   • Belgisch Genootschap voor Farmaceutische Wetenschappen (BGFW);
   • Belgisch Genootschap voor Gerechtelijke Geneeskunde (BGGG).

Service Activities (external):

• Head of the Laboratory of Forensic Toxicology
  • Follow-up of routine casework in judicial cases since Jan 1st 2008
  • End responsible (lab director) since Sept 15, 2014
  • Provided many hundreds of reports to the Department of Justice
  • Expert witness in court
• Core member of the Forensic Institute of Ghent University (FI-UGent).
• Toxicological consultancy; ad hoc toxicological expertise (e.g. Superior Health Council, Fonds Medische Ongevallen).
• Involved in providing toxicological expertise in the train disaster at Wetteren (Belgium) (May 2013 - on-site expertise, scientific publications, part of the superior health council, report to federal minister of public health, …).
• Recognized by the Department of Justice as expert for determination of alcohol in cases of drunk driving (since Sept 4, 2014).
• Director of the ISO 17025/1595 accredited Reference Laboratory Ref4U, implementing reference measurement procedures for e.g. thyroid hormones and vitamin D.